Cellverse is developing AI-based digital twins, high-performance bioinks, and bioprinted 3D in-vitro disease models that replicate complex tissue pathology. Our integrated platform enables precise fabrication, predictive analysis, and clinically relevant drug testing, accelerating oncology research, biomarker discovery, therapeutic screening, and personalized medicine development with improved reliability, efficiency, and translational impact. Currently, we are working on obtaining certifications and regulatory approval.